Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07847398 | Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.(EMMENEO-TN) | not yet recruiting | N/A | 50 | Centre Antoine LacassagneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 |
| clinicaltrials |
| NCT07844759 | SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers(SOLIS) | not yet recruiting | N/A | 30 | Renaissance Institute of Precision Oncology and RadiosurgeryOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07419880 | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer(RECLAIM) | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840534 | Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)(LYSA2PIFU) | not yet recruiting | N/A | 30 | University College CorkOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | not yet recruiting | Phase 2 | 750 | The University of The West IndiesOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT07828652 | Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) | not yet recruiting | — | 2,000 | Yeon Hee ParkOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819981 | Prehabilitation for Improving Outcomes in Breast Cancer Patients Undergoing Neoadjuvant Systemic Treatment and Surgery | not yet recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07801898 | Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer | not yet recruiting | Phase 2 | 36 | The Second Hospital of Anhui Medical UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06926530 | Herbs & Supplements in Breast Cancer Usage, Impact, and Personalized Approaches for Diverse Populations | not yet recruiting | — | 240 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | not yet recruiting | Phase 3 | 436 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC(DETENTE-1) | not yet recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787338 | SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | not yet recruiting | Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | not yet recruiting | Phase 2 | 48 | Yonsei UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07558343 | Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2(MATADOR2) | not yet recruiting | N/A | 120 | Institut Claudius RegaudOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.(DUNP19) | not yet recruiting | Phase 1 | 16 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC(SCHBCC-N0117) | not yet recruiting | Phase 3 | 180 | Fudan UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07752550 | Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 120 | Harbin Medical UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer(ADAPT-TN-IV) | not yet recruiting | Phase 3 | 765 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 50 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748260 | De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast(neoDIRHP) | not yet recruiting | Phase 3 | 592 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC(NeoASPECT) | not yet recruiting | Phase 2 | 110 | University of Kansas Medical CenterOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07151586 | Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer(ALTER) | not yet recruiting | Phase 2 | 260 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07729046 | Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07458113 | Sac-TMT for Active TNBC Brain Metastases(BERLIN) | not yet recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726342 | SMP-656 for HER2-Positive Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Chengdu SciMount Pharmatech Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07606287 | Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital | not yet recruiting | N/A | 4,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721259 | A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden | not yet recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07717450 | Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.(TAILORswitch) | not yet recruiting | Phase 3 | 370 | UNICANCEROTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease(TIBEC) | not yet recruiting | Phase 1 / Phase 2 | 154 | National University Hospital, SingaporeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07672431 | Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression | not yet recruiting | N/A | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07671690 | Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data | not yet recruiting | N/A | 1,800 | Yunnan Cancer HospitalOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07662252 | Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer(NEOSHED) | not yet recruiting | — | 186 | Federico II UniversityOTHER | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07657442 | Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer | not yet recruiting | N/A | 649 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07635654 | Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses(DELILA) | not yet recruiting | N/A | 43 | KU LeuvenOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07357948 | Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy(OMICHIR) | not yet recruiting | N/A | 150 | Institut CurieOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | not yet recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | not yet recruiting | Phase 3 | 562 | SWOG Cancer Research NetworkNETWORK | 0 | May 27, 2026 | clinicaltrials |
| NCT07605195 | Research on the Whole-Process Intelligent Diagnosis and Treatment of Digital Breast Tomosynthesis Based on Deep Learning | not yet recruiting | N/A | 5,000 | Yunnan Cancer HospitalOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials